Single-arm trials for US Food and Drug Administration cancer drug approvals

被引：0
|
作者：
Nierengarten, Mary Beth
机构：
来源：
CANCER | 2023年 / 129卷 / 11期
关键词：
D O I：
10.1002/cncr.34830
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, we explore why using single-arm studies for accelerated US Food and Drug administration approvals can help get drugs previously approved for other uses to patients with cancer. In addition, new studies show that adherence to evidence-based surgical metrics improves long-term outcomes in patients with early-stage lung cancer, and lung cancer screening based on personal lung cancer risk is more cost-effective than screening based on age and smoking history.
引用
收藏
页码：1626 / 1627
页数：2
相关论文
共 50 条
  • [1] Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
    Agrawal, Sundeep
    Arora, Shaily
    Amiri-Kordestani, Laleh
    de Claro, R. Angelo
    Fashoyin-Aje, Lola
    Gormley, Nicole
    Kim, Tamy
    Lemery, Steven
    Mehta, Gautam U.
    Scott, Emma C.
    Singh, Harpreet
    Tang, Shenghui
    Theoret, Marc R.
    Pazdur, Richard
    Kluetz, Paul G.
    Beaver, Julia A.
    [J]. JAMA ONCOLOGY, 2023, 9 (02) : 266 - 272
  • [2] Single-arm trials for domestic oncology drug approvals in China
    Hong Zhang
    Sen Liu
    Chenghao Ge
    Xiaozhen Liu
    Yang Liu
    Chen Yin
    Yi Li
    Jing An
    Zhongtian Yan
    Xiaoyuan Chen
    [J]. Cancer Biology & Medicine, 2023, (11) : 799 - 805
  • [3] Single-arm trials for domestic oncology drug approvals in China
    Zhang, Hong
    Liu, Sen
    Ge, Chenghao
    Liu, Xiaozhen
    Liu, Yang
    Yin, Chen
    Li, Yi
    An, Jing
    Yan, Zhongtian
    Chen, Xiaoyuan
    [J]. CANCER BIOLOGY & MEDICINE, 2023, 20 (11) : 799 - 805
  • [4] Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials
    Tibau, Ariadna
    Molto, Consolacion
    Borrell, Maria
    Del Paggio, Joseph C.
    Barnadas, Agusti
    Booth, Christopher M.
    Amir, Eitan
    [J]. JAMA ONCOLOGY, 2018, 4 (11) : 1610 - 1611
  • [5] Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration
    Hilal, Talal
    Gonzalez-Velez, Miguel
    Prasad, Vinay
    [J]. JAMA INTERNAL MEDICINE, 2020, 180 (08) : 1108 - 1115
  • [6] Magnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA)
    Molto Valiente, C.
    Borrell, M.
    Ocana Fernandez, A.
    Templeton, A. J.
    del Carpio, L. P.
    Del Paggio, J.
    Barnadas, A.
    Booth, C. M.
    Tibau, A.
    Amir, E.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 564 - 564
  • [7] Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies
    Rittberg, Rebekah
    Czaykowski, Piotr
    Niraula, Saroj
    [J]. JNCI CANCER SPECTRUM, 2021, 5 (04)
  • [8] Food and Drug Administration approvals in phase 3 Cancer clinical trials
    Joseph Abi Jaoude
    Ramez Kouzy
    Marc Ghabach
    Roshal Patel
    Dario Pasalic
    Elie Ghossain
    Austin B. Miller
    Timothy A. Lin
    Vivek Verma
    C. David Fuller
    Vivek Subbiah
    Bruce D. Minsky
    Ethan B. Ludmir
    Cullen M. Taniguchi
    [J]. BMC Cancer, 21
  • [9] Food and Drug Administration approvals in phase 3 Cancer clinical trials
    Jaoude, Joseph Abi
    Kouzy, Ramez
    Ghabach, Marc
    Patel, Roshal
    Pasalic, Dario
    Ghossain, Elie
    Miller, Austin B.
    Lin, Timothy A.
    Verma, Vivek
    Fuller, C. David
    Subbiah, Vivek
    Minsky, Bruce D.
    Ludmir, Ethan B.
    Taniguchi, Cullen M.
    [J]. BMC CANCER, 2021, 21 (01)
  • [10] Core limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration.
    Hilal, Talal
    Gonzalez-Velez, Miguel
    Prasad, Vinay
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345